Press Releases
AIM ImmunoTech Provides Update Regarding Annual Meeting
AIM Will Convene Annual Meeting on December 1st and then Adjourn Until December 29th to Give Delaware Court Additional Time to Deliver Ruling in Activist Group Litigation OCALA, Fla. - AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced...
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this means in a brief video: here OCALA, Fla., Nov. 27, 2023 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today...
AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
No severe adverse events reported to date Topline data expected as early as Q1 2024 OCALA, Fla., Nov. 21, 2023 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced the last subject has completed treatment in the Company's Phase 2 study...
Stock Information
Recent SEC Filings
Corporate Presentation